Abstract. The identification of several types of familial colorectal cancer has led to the discovery of some of the genes involved in these diseases. It was subsequently shown that somatic mutations of these genes (APC, mismatch repair genes, TP53, KRAS, and DCC) also occur in sporadic colorectal cancer. Gradually, this molecular information is being incorporated into the standard histopathological analysis of colorectal cancer and can be used for the characterization of primary tumors. Although attempts have been made to use molecular parameters to better define dysplasia grades, differentiate between adenoma and carcinoma, and subtype carcinomas, histological parameters remain the standard for the classification of primary tumors. Nonetheless, molecular parameters may help define subgroups of colorectal carcinoma differing in prognosis and requiring individualized treatment regimens. Interesting possibilities are predicting the response to chemotherapy or radiotherapy at a molecular level and the search for metastasis by looking for molecular markers in lymph nodes or circulating blood. Other pathological tests being developed include the detection of KRAS, TP53, or APC mutations in stool and plasma. Such approaches will have a significant impact on the clinical management of colorectal cancer.
Colorectal cancer is a significant health problem in the Western world. Environmental factors play an important role in its etiology, with nutritional factors probably of crucial impact. In less than 10 % of cases a familial cancer syndrome is involved, and in this situation genetic factors dominate. The most prevalent of these syndromes have been clarified at a molecular genetic level in recent years. Most colon cancers arise through gradual malignant progression of a benign precursor lesion known as an adenoma (Fig. 1 ). This stepwise progression has been studied intensively in the last decade from a molecular genetic point of view. These investigations have led to the concept of molecular genetic carcinogenic progression, first published a decade ago by Vogelstein's group (Fearon and Vogelstein, 1990 ) and recently updated (Kinzler and Vogelstein, 1996) . Colon cancer is one of the best characterized tumors from a molecular genetic point of view, and the model of progression due to stepwise accumulation of genetic abnormalities serves as a paradigm for many other neoplasms. In this review the use of molecular genetics in the pathological analysis of colorectal cancer-including classification of primary disease, therapeutic response, prognosis, detection of disease spread, and population screening-is discussed.
Characterization of primary lesions
In characterizing a polypectomy or colectomy specimen, the pathologist may have to answer the following questions: is this a sporadic or familial disease, what is the nature of the lesion in the adenoma-carcinoma sequence, and, in the case of a carcinoma, is this a particular subtype?
Sporadic or familial disease
The question of whether a colorectal neoplasm is sporadic or familial is rarely addressed by the pathologist. Nevertheless, there is a role for pathology in two areas: recognition of variants of familial disease through particular forms of pathological presentation, and the recognition of hereditary nonpolyposis colorectal cancer (HNPCC) through microsatellite instability in the tumor.
Pathology has been an important determinant in the recognition of particular variants of familial adenomatous polyposis (FAP), e.g., the attenuated variant of FAP, or AFAP (Lynch et al., 1995) . In studying an autosomal dominantly inherited syndrome characterized by right-sided colonic adenomas, colorectal carcinomas, gastric fundic gland polyps, and duodenal adenomas, the investigators recognized the flat, rather than polypoid, nature of the adenomas (Fig. 2) (Lynch et al., 1990 (Lynch et al., , 1993 . Subsequently, it was found that this phenotype is associated with a mutation in the extreme 5) end of the APC gene, resulting in a truncated 16-kDa polypeptide. In patients with HNPCC, the colorectal lesions (adenomas and carcinomas) are characterized by a high frequency of DNA replication errors due to germline mutations in the genes involved in DNA nucleotide mismatch repair (MSH2, MLH1, PMS1, PMS2, and MSH6) (Kinzler and Vogelstein, 1996; Akiyama et al., 1997; Miyaki et al., 1997) . In a recent study on microsatellite instability in over 500 tumors, Aaltonen et al. (1998) found that 12 % had replication errors, of which about 16 % had germline mutations in MLH1 or MSH2. The authors proposed replication error testing of tumor tissue in all cases with a family history of colon or endometrial cancer, an age of less than 50 yr, or a history of multiple colon and/or endometrial cancers. Positive cases should then be further tested for germline mutations in mismatch repair genes. In a reaction to this study, Lynch and Smyrk (1998) contested this conclusion; they regarded the family history as the crucial criterion and objected to microsatellite instability as an exclusion criterion.
The nature of colorectal proliferative lesions In this context, two different pathways of colorectal carcinogenesis have to be discussed: the adenoma-carcinoma sequence (Fig. 2) , as it occurs in sporadic as well as familial CRC, and the dysplasia-carcinoma sequence, as it occurs in inflammatory bowel disease.
In the adenoma-carcinoma sequence, it is widely accepted that aberrant crypt foci (ACF) are the earliest identifiable lesions (Fig. 3) . These early lesions were initially recognized in chemically induced rodent colorectal carcinogenesis (Whiteley et al., 1996) but were also later identified in the human colon (Nucci et al., 1997) . A recent study by Bouzourene et al. (1998) has revealed that ACF can be microscopically associated with crypt hyperplasia, with or without cellular atypia, or with frank dysplasia (Fig. 4) . Interestingly, only dysplastic ACF occurred more frequently in colorectal carcinoma-associated colon mu- cosa, the other ACF histologies occurring more frequently in benign colorectal disease. ACF dysplasia is associated with mutations in the APC genes . In contrast, KRAS mutations occur rather more often in these lesions, but irrespective of their morphology. TP53 mutations were rare in these lesions (Losi et al., 1996) . These findings are compatible with the concept that dysplastic ACF constitute the earliest step in colorectal carcinogenesis and are primarily associated with APC mutations, with KRAS mutations not being an important determinant in this phase and TP53 mutations occurring later in the sequence. It is likely that ACF without dysplasia develop into endoscopically identifiable hyperplastic polyps, whereas ACF with dysplasia might develop into adenomas (Otori et al., 1995) .
The subsequent steps in the adenoma-carcinoma sequence are less fiercely debated. Grading of dysplasia is routinely performed in the histological assessment of polypectomy specimen and is somewhat correlated with the likelihood of a synchronous or metachronous lesion. However, given the very low recurrence rate of adenomas after polypectomy, grading is not of primary importance for the determination of further treatment or follow-up. It is generally agreed that TP53 mutations occur relatively frequently only in high-grade dysplastic polyps. However, given the limited impact of adenoma grading, routine molecular genetic analysis of adenomas is not warranted. Recently, Saraga et al. (1997) found heterogeneity of KRAS mutations in adenomas, with some adenomas containing multiple (sub)clones of tumor cells with different KRAS mutations. Such molecular genetic heterogeneity shows that subclones with different genetic aberrations can coexist in a neoplasm.
Histologically, the transition from a noninvasive adenoma to an invasive carcinoma is mostly readily identifiable, but it does not have a clearly defined molecular corollary. Molecular genetic analysis does not provide unambiguous indicators in cases of doubt.
Carcinoma subtype
A variety of morphological subtypes have been distinguished among colorectal cancers, including different degrees of differentiation (Hermanek, 1989) , carcinomas with endocrine differentiation (de Bruine et al., 1993) , and mucinous carcinomas. Although the association of the latter subtype with HNPCC has been established, this does not merit systematic routine molecular genetic evaluation.
In conclusion, a routine molecular genetic analysis is not warranted for histopathological evaluation of a polypectomy or a (partial) colectomy specimen for the purposes of classification of a primary tumor. A possible exception is that of microsatellite instability in cases with a reasonable suspicion of HNPCC because of age, family history, and cancer multiplicity.
The dysplasia-adenoma sequence in inflammatory bowel disease
The development of colorectal carcinoma is an important risk in inflammatory bowel disease. This holds particularly true for ulcerative colitis, with a cumulative risk of 7-14 % 20 yr after onset of the disease (Tytgat et al., 1995) . In Crohn's disease the incidence of colorectal carcinoma is also elevated, but much less so than in ulcerative colitis, although the cancer risk in Crohn's disease seems to be increasing (Gillen et al., 1994) . It has been shown that ulcerative colitis does not develop through an adenoma-carcinoma but through flat dysplastic lesions, initially with limited epithelial atypia and low cancer risk. Such lesions can progress to high-grade dysplasia and may then present endoscopically visible lesions, which are often associated with a colorectal carcinoma. It has become standard practice to survey ulcerative colitis patients endoscopically and take biopsies of abnormal mucosa in the search for dysplasia (Fig. 5) .
However, flat dysplastic lesions are very difficult to recognize by endoscopy, and most biopsies are taken at random, limiting the usefulness of this approach. A second problem is the limited reproducibility of histopathological dysplasia grading due to subjective interpretation. Studies have attempted to identify early molecular changes in the dysplastic lesions. Chaubert et al. (1994) reported that KRAS and TP53 mutations occur in long-standing ulcerative colitis, even in nondysplastic mucosa. The frequency of KRAS, TP53, and APC mutations in ulcerative colitis-associated colorectal carcinoma is lower than in other forms of colorectal carcinoma (Tarmin et al., 1995) , suggesting that the molecular pathway of colorectal carcinoma development in ulcerative colitis differs significantly from that in sporadic or familial colorectal cancer. Furthermore, molecular genetic alterations cannot be used as an identification parameter for (pre)malignant change, since they also occur in morphologically nonneoplastic mucosa. Given these limitations of biopsy-supported endoscopic surveillance, some surgeons advocate prophylactic colectomy after 10 yr of active ulcerative colitis. Standard practice remains, however, to survey, biopsy, and-in the case of endoscopic or microscopic lesions-perform a colectomy with dysplasia, regardless of its degree, as the leading histological parameter.
Response to therapy
For colorectal cancer the most important therapeutic approach remains surgery. Chemotherapy, radiotherapy, and immunotherapy are additional modalities that can be considered in particular situations, most notably preoperative radiotherapy before surgical resection of a rectal carcinoma (Aleman et al., 1995) and adjuvant chemotherapy in advanced colon carcinoma (Haller, 1995) . Such therapeutic approaches are not without side effects, and the question can be asked whether molecular genetic analysis of the primary tumor might provide clues as to the sensitivity of a particular cancer for chemotherapy and/ or radiotherapy.
Most studies have investigated the correlation between mutations in apoptosis-associated genes and response to chemotherapy or radiotherapy. Benhattar et al. (1996) studied TP53 mutations in advanced (Dukes stage D) colorectal carcinomas treated with 5-fluorouracil and found short survival of patients having a tumor with a TP53 mutation. Palazzo et al. (1997) found TP53 and BCL2 expression in a high proportion of colorectal carcinoma cases that had proven radioresistant.
Approaches using only a small selection of the genes implicated in apoptosis seems, however, somewhat simplistic. Given the extreme complexity of apoptosis regulation and the likelihood that not only tumor cell apoptosis but also necrosis, e.g., due to therapy effects on the tumor vasculature, is involved, much additional work needs to be done to advance this field.
Determinants of prognosis
The goal of prognosis determination is to define homogeneous diagnostic subgroups on the basis of clinical, morphological, or molecular parameters, to which a particular prognosis can be attributed. In colorectal cancer the most important prognostic factor is disease stage, defined according to the Dukes system. This gives a 5-yr survival of 85 % for Dukes stage A, 65 % for stage B, and 35 % for stage C. However, since 50 % of all cases present in Dukes stage B, additional parameters allowing subdivision of this category into more homogeneous subgroups would be important.
Molecular genetic features have been amply considered as a parameter. KRAS mutations have been most frequently studied. Some groups have concluded that the presence of a KRAS mutation conveys information relevant for prognosis, but at least as many reports claim that this is not the case. The same mutation has been claimed to be associated with poor prognosis by some and with good prognosis by others. Recently, Andreyev et al. (1998) pooled the data from 22 different groups to derive over 2,500 patients. The presence of any KRAS mutation was associated with increased risk to recurrent disease and death, with the valine codon 12 mutation making the largest contribution.
The prognostic value of TP53 is also conflicting. Here the distinction has to be made between studies on TP53 mutation and those on p53 protein overexpression. Most papers on overexpression indicate the absence of a convincing correlation between p53 expression and prognosis. However, TP53 mutations appear to be associated with an unfavorable prognosis (Hamelin et al., 1994; Goh et al., 1995; Smith et al., 1996) ; mutations in the zinc-binding domain, in particular, seem to be prognostically unfavorable (Børresen-Dale et al., 1998) . Chen et al. (1997) examined the frequency of microsatellite instability in sporadic colorectal cancer and found an association with advanced colorectal cancer and recurring disease. However, Bubb et al. (1996) reported that sporadic colorectal cancer patients with microsatellite instability had a better prognosis than those without. This suggests that the role of microsatellite instability as a potential prognostic factor clearly needs further investigation. An interesting link has been found between microsatellite instability and mutations in the TGFß type II receptor gene. A polyadenine stretch in the gene is relatively sensitive to mismatch errors and mutation ensues. TGFß-IIR mutated tumors occurred more frequently in the right colon (Akiyama et al., 1996) and, given their similarity with HNPCC-associated cancers, might behave relatively favorably. A direct correlation between TGFß-IIR and prognosis in sporadic colorectal cancer clearly needs to be further investigated. Recently, members of the SMAD family of molecules, implicated in TGFß downstream signaling, have been implicated as tumor suppressor genes in colorectal cancer (Takagi et al., 1998) . Their use in other diagnostic workups is not yet clear. demonstrated that 18q loss was a strong independent predictor of survival. Stage II tumors with 18q loss behaved as stage III tumors. More recently, Shibata et al. (1996) found that loss of the DCC protein on 18q was a strong predictor of shorter 5-yr survival. As in the Jonas et al. (1996) study, stage II tumors with loss of DCC expression behaved as stage III tumors.
Tumor extension
Tumor extension, especially the presence of lymph-node metastasis, is one of the most important prognostic indicators. Traditionally, lymph-node metastasis is established through histological examination of lymph nodes excised with the resection specimens. Recently, two new approaches have been investigated: the identification through PCR of the presence of cancer cells in either lymph-node tissue or the peripheral blood/ bone marrow. Cytokeratin 20 (Gunn et al., 1996) , matrilysin (Ichikawa et al., 1998) , and CD44 (Wong et al., 1997) have been used as markers to detect metastasis in lymph nodes. Analysis of venous blood isolates (Fujita et al., 1996; Jonas et al., 1996; Soeth et al., 1997) has shown that significant numbers of tumor cells are liberated into the venous effluent blood during colectomy.
Overall, these results indicate that tumor cells circulate in the blood and are also found in lymph nodes much more frequently than had been assumed on the basis of histological analyses. The prognostic value of these observations remains to be established.
Population screening
Screening for sporadic colorectal cancer is an important issue. However, the incidence of adenomas in the general population is so high that colonoscopic screening is not a realistic option. Therefore prescreening procedures that can identify patients at increased risk are urgently needed. One approach used for decades is screening for occult fecal blood loss. Two alternative approaches have been proposed in the last few years: detection of mutant genes in DNA in plasma or serum or in the feces. Kopreski et al. (1997) studied circulating DNA in untreated colorectal cancer patients and in normal controls. Thirty-nine percent of the cancer patients, but none of the controls, exhibited KRAS mutations as detected by PCR and sequencing. However, KRAS might not be tumor specific and, conversely, the sensitivity might fall short of what would be expected from an effective screening tool. Given the relative simplicity of the procedure, however, it merits thorough investigation.
Several studies have published procedures to screen for gene mutations in feces: Sidransky et al. (1992) and Nollau et al. (1996) for KRAS, Eguchi et al. (1996) for TP53, and Deuter et al. (1998) for APC. No studies on early detection of asymptomatic individuals have been published as yet. However, with more automation and increased sensitivity of PCR-based methods, fecal screening for colorectal cancer seems within reach.
